Amgen’s Post

For National Cancer Research Month, we want to say thank you to our team and the researchers, clinicians, and patients who are taking part in clinical trials to advance new therapeutics. We've made important progress, but there is still much to be done. Together, we can push forward and make a difference in the lives of those affected by #cancer. Learn more about our #clinicaltrials and the contributions Janux is making to #cancerresearch: https://lnkd.in/ggvVSxn3 #NCRM24 #CancerResearchSavesLives #TCellEngagers #cancer #oncology #immunotherapy #immunomodulators

Results from our Phase 3 clinical trial evaluating treatments for patients with advanced ALK-positive NSCLC shared at American Society of Clinical Oncology (ASCO) 2024 Albert Bourla Pfizer #ASCO24 #Cancer #LCSM #NSCLC #ClinicalTrials #OncoDaily #Oncology

🎗️ 📢 Prostate Cancer Awareness Month📢🎗️ September 1st marked the start of Prostate Cancer Awareness Month. This month serves as a crucial reminder of the importance of understanding Prostate Cancer. Becoming aware of the risks and symptoms of Prostate Cancer could lead to earlier diagnosis and more effective treatments. Throughout this month, Verity Pharmaceuticals will be sharing valuable insights, facts, and resources on Prostate Cancer. Stay tuned to our page so you don’t miss a post! #MensHealth #ProstateCancerAwareness #PCAM #ProstateCancer

The addition of tiragolumab, an anti-TIGIT inhibitor, to chemotherapy plus atezolizumab demonstrated promising early results for lung cancer. Unfortunately, the phase 3 study SKYSCRAPER-02 did not confirm the anticipated benefit of tiragolumab combination in recalcitrant small-cell lung cancer, reiterating the need for a more accurate population selection in clinical trials. Read Viewpoint in #Med. https://lnkd.in/eEK5VPMV #lungcancer #clinicaltrial #tiragolumab #TIGIT #SKYSCRAPER-02

Exciting news in the world of cancer treatment! The phase 2b KEYNOTE-942 trial has shown that combining Moderna's personalized mRNA-4157 cancer vaccine with Merck's pembrolizumab (Keytruda) significantly improves outcomes for high-risk melanoma patients. This combination therapy reduced the risk of recurrence or death by an impressive 44%, and patients experienced a meaningful improvement in recurrence-free and distant metastasis-free survival. The FDA has granted this combination Breakthrough Therapy Designation, and further phase 3 trials are underway. #Healthcare #mRNA #Melanoma #CancerResearch #ClinicalTrials

New FDA-Approved Targeted Drug for Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer Precision Oncology specialist, Alex Rolland, discusses a new recently FDA-approved targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. Watch this video to learn What new treatment has recently been approved Exploring the results of the CAPItello-291 trial How these results led to the treatment being FDA-approved Who this treatment will work for Explanation of statistics used in this trial What tests a patient needs to determine if this treatment will work for them Next steps patients can take to access this treatment Alex is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share key takeaways about this new treatment, including how to access it through a patient's current treatment team. Click to watch 👉https://buff.ly/3TSsP3I 👀 #HopeIsHere #PrecisionCancerMedicine

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer.TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer.Conversion to full approval from accelerated approval is based on positive results from global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy

Locally Advanced Pancreatic Cancer Market Report 2023-2028: Recent Advancements in Immunotherapy Inject New Hope into LAPC Market: DUBLIN, Nov. 21, 2023 /PRNewswire/ -- The "Locally Advanced Pancreatic Cancer Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F" report has been added to ResearchAndMarkets.com's offering. The dynamic and complex healthcare sector focuses on the diagnosis,...

This post is intended for a US audience:   Today we announced the US FDA granted Priority Review for our HER2-directed antibody drug conjugate (ADC) – which we develop in collaboration with Daiichi Sankyo – for the potential treatment of certain patients with metastatic HER2-positive solid tumors.   HER2-directed therapies have been used for decades in breast cancer, where they have transformed outcomes for patients. Only recently has HER2 emerged as a treatment target for other types of solid tumors, creating an opportunity for us to address an important unmet need in patients. If approved, our ADC would potentially be the first HER2-directed treatment to receive a tumor-agnostic indication, aiding in our mission to redefine cancer care. Learn more about the news: https://lnkd.in/e_8Rajn3 #USOnly #AstraZenecaUS